AJPB

Trends in Medication Utilization and the Cost of Treatment for Gout

Published Online: June 07, 2013
Lauren Meyer, PharmD; Cassandra Ford, PharmD; Kristen Harrison, MPH; Nirmal K. Ghuman, PharmD, MPH; Olga S. Matlin, PhD; Anthony Palmieri, RPh, PharmD; and Steven M. Kymes, PhD
Gout is a rheumatic disease affecting nearly 3.9% (8.3 million) of adults in the United States, with men almost 40% more likely to beafflicted than women.1,2 Hyperuricemia, or elevated uric acid levels greater than 6.8 mg/dL, which result in the formation of monosodium urate crystals in joint tissues, is the primary cause of gout.3,4 Gout initially presents as an acute episode of arthritis, most commonly beginning in the metatarsalphalangeal joint at the base of the big toe.5 Risk factors for gout include lifestyle-related behaviors such as alcohol use and consumption of purine-rich foods, in particular organ meats and oily fishes.6 Medical conditions including obesity, diabetes, and renal insufficiency contribute to the risk of gout, as do medications such as diuretics and chemotherapeutic agents.6 The treatment goals for acute and chronic gout differ, as do the medications used in each setting (Table 1).7,8 The goal of treatment for an acute episode of gout is pain relief through reduction of inflammation.7 This is often achieved by the use of over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs), prescription corticosteroids, or colchicine. For patients with chronic gout, the goal of treatment is to reduce the frequency of painful episodes by reducing and maintaining uric acid concentrations of less than 6 mg/dL using a combination of nonpharmacological interventions (ie, dietary and lifestyle changes) and pharmacological agents.7

The American College of Rheumatology (ACR) has recommended first-line pharmacologic prophylaxis with a xanthine oxidase inhibitor (XOI), such as allopurinol or febuxostat, along with low-dose colchicine or an NSAID in treatment of chronic gout.8 Probenecid, a uricosuric, is recommended as an alternative first-line agent when either allopurinol or febuxostat is contraindicated or when a patient has demonstrated intolerance to at least 1 of the first-line agents.7 The ACR further designated the combination of an XOI and a uricosuric as a second-line treatment in refractory disease. A newer therapeutic option, pegloticase, is a recombinant uricase reserved as a third-line agent in cases of refractory disease where a patient has failed or was not able to tolerate an appropriately dosed oral urate-lowering therapy. Pegloticase is administered biweekly by infusion in a healthcare setting.9 

Until recently the cost of medication for the treatment of chronic gout was relatively low, with the monthly cost for a single medication ranging from $18 to $100, depending on disease severity and duration.10 However, treatment of chronic gout may require multiple medications, and the combined economic burden has been estimated by some investigators to be over $200 per month.11 The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. In June 2006, the US Food and Drug Administration (FDA) initiated a new drug safety proposal to remove medications, such as colchicine, from the market that previously had not been required to demonstrate safety or efficacy.12 In order to incentivize evaluation of medications impacted by this initiative, the FDA offered marketplace exclusivity to companies that conducted the necessary safety and efficacy studies.12,13 In 2007, URL Pharma, a maker of generic medications (since acquired by Takeda Pharmaceutical Company Limited), conducted clinical trials to examine the efficacy of colchicine and identify the smallest efficacious dose for the treatment of gout.13 A lower-dose regimen with an incidence of adverse events similar to placebo was identified and in 2009 the manufacturer was granted 3 years of marketplace exclusivity for their colchicine formulation, Colcrys.13,14 Following this approval, the FDA mandated the removal of all unapproved single-ingredient oral colchicine products from the market resulting in an unintended increase in the cost of treatment from pennies per day to nearly $5 per day.12,13 

This report will examine the prevalence of prescription medications utilized in the treatment of gout. In addition, the influence of Colcrys on utilization and cost of treatment for gout will be analyzed. Finally, the current status and economic consequence of recently launched and pipeline medications used for the treatment of gout will be discussed.

METHODS

This descriptive analysis was conducted using de-identified CVS Caremark pharmacy claims data. Adult members who had a pharmacy claim in calendar years from 2009 to 2012 for at least 1 of the medications primarily used for the treatment of gout were selected for analysis. The medications considered were: colchicine, febuxostat, pegloticase, colchicine with probenecid, and allopurinol. Age and gender were based upon that reported for the last claim for each member. The generic dispensing rate (GDR) and cost per utilizer per day were also calculated. For this analysis, “cost” is defi ned as the total paid charges for the medication (the payer and member portions combined). The descriptive analyses were conducted using SAS 9.1 (SAS Institute, Cary, North Carolina).  

RESULTS

 A total of 955,356 unique members were identified with a pharmacy claim for at least 1 gout medication. This reflects a prevalence of 1.5% among adult members, which remained stable over the observation period (2009-2012). The average age of members with gout was 62.8 years (standard deviation ±14.2) and 75.9% of members utilizing prescription gout medications were male. The prevalence of gout varied by payer type (Figure 1), and as would be expected due to their older age, gout was more common among members in Medicare plans than members in other plans. Members in Medicaid plans had the lowest prevalence of gout. This is likely an artifact of coverage policies for prescription medications for treatment of gout in these plans and the high prevalence of young women and children among Medicaid beneficiaries.

PDF is available on the last page.

Issue: May/June 2013
More on AJMC.COM